The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit
Open accessAbstract
IMPORTANCE: Coenzyme Q10 (CoQ10), an antioxidant that supports mitochondrial function, has been shown in preclinical Parkinson disease (PD) models to reduce the loss of dopamine neurons, and was safe and well tolerated in early-phase human studies. A previous phase II study suggested possible clinical benefit. OBJECTIVE: To examine whether CoQ10 could slow disease progression in early PD. DESIGN, SETTING, AND PARTICIPANTS: A phase III randomized, placebo-controlled, double-blind clinical trial at 67 North American sites consisting of participants 30 years of age or older who received a diagnosis of PD within 5 years and who had the following inclusion criteria: the presence of a rest tremor, bradykinesia, and rigidity; a modified Hoehn and Yahr stage of 2.5 or less; and no anticipated need for dopaminergic therapy within 3 months. Exclusion criteria included the use of any PD medication within 60 days, the use of any symptomatic PD medication for more than 90 days, atypical or drug-induced parkinsonism, a Unified Parkinson's Disease Rating Scale (UPDRS) rest tremor score of 3 or greater for any limb, a Mini-Mental State Examination score of 25 or less, a history of stroke, the use of certain supplements, and substantial recent exposure to CoQ10. Of 696 participants screened, 78 were found to be ineligible, and 18 declined participation. INTERVENTIONS: The remaining 600 participants were randomly assigned to receive placebo, 1200 mg/d of CoQ10, or 2400 mg/d of CoQ10; all participants received 1200 IU/d of vitamin E. MAIN OUTCOMES AND MEASURES: Participants were observed for 16 months or until a disability requiring dopaminergic treatment. The prospectively defined primary outcome measure was the change in total UPDRS score (Parts I-III) from baseline to final visit. The study was powered to detect a 3-point difference between an active treatment and placebo. RESULTS: The baseline characteristics of the participants were well balanced, the mean age was 62.5 years, 66% of participants were male, and the mean baseline total UPDRS score was 22.7. A total of 267 participants required treatment (94 received placebo, 87 received 1200 mg/d of CoQ10, and 86 received 2400 mg/d of CoQ10), and 65 participants (29 who received placebo, 19 who received 1200 mg/d of CoQ10, and 17 who received 2400 mg/d of CoQ10) withdrew prematurely. Treatments were well tolerated with no safety concerns. The study was terminated after a prespecified futility criterion was reached. At study termination, both active treatment groups showed slight adverse trends relative to placebo. Adjusted mean changes (worsening) in total UPDRS scores from baseline to final visit were 6.9 points (placebo), 7.5 points (1200 mg/d of CoQ10; P = .49 relative to placebo), and 8.0 points (2400 mg/d of CoQ10; P = .21 relative to placebo). CONCLUSIONS AND RELEVANCE: Coenzyme Q10 was safe and well tolerated in this population, but showed no evidence of clinical benefit. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00740714.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472
Self-citationRecent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Self-citationMitochondrial biology and oxidative stress in Parkinson disease pathogenesis
Henchcliffe, C., & Beal, M. F. (2008) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0924 · Cited by 783
Self-citationSnow, B. J., Rolfe, F. L., Lockhart, M. M., Frampton, C. M., O'Sullivan, J. D., Fung, V., Smith, R. A. J., Murphy, M. P., Taylor, K. M., & On behalf of the Protect Study Group (2010) · Movement Disorders · doi:10.1002/mds.23148 · Cited by 606
Energy metabolism defects in Huntington's disease and effects of coenzyme Q10
Koroshetz, W. J., Jenkins, B. G., Rosen, B. R., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410206 · Cited by 405
Self-citationShults, C. W., Haas, R. H., Passov, D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410420221 · Cited by 326
Self-citationPlasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations
Bhagavan, H. N., & Chopra, R. K. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.03.003 · Cited by 243
Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease
Shults, C. W., Flint Beal, M., Song, D., & Fontaine, D. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.05.003 · Cited by 223
Self-citationA randomized clinical trial of coenzyme Q 10 and GPI-1485 in early Parkinson disease
The NINDS NET-PD Investigators (2007) · Neurology · doi:10.1212/01.wnl.0000250355.28474.8e · Cited by 219
Self-citationStorch, A. (2007) · Archives of Neurology · doi:10.1001/archneur.64.7.nct60005 · Cited by 205
MIXED LINEAGE KINASE INHIBITOR CEP- 1347 FAILS TO DELAY DISABILITY IN EARLY PARKINSON DISEASE
Wang, L. H., & Johnson, E. M. (2008) · Neurology · doi:10.1212/01.wnl.0000324506.93877.5e · Cited by 204
Coenzyme Q10 and statins: Biochemical and clinical implications
Littarru, G. P., & Langsjoen, P. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.03.002 · Cited by 188
Coenzyme Q10 effects in neurodegenerative disease
Henchcliffe, C. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5212 · Cited by 188
Self-citationMitochondrial Contribution to Parkinson's Disease Pathogenesis
Schapira, A. H. V., & Gegg, M. E. (2011) · Parkinson s Disease · doi:10.4061/2011/159160 · Cited by 169
Cooper, J. M., Korlipara, L. V. P., Hart, P. E., Bradley, J. L., & Schapira, A. H. V. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02318.x · Cited by 163
Stamelou, M., Reuß, A., Pilatus, U., Magerkurth, J., Niklowitz, P., Eggert, K. M., Krisp, A., Menke, T., Schade‐Brittinger, C., Oertel, W. H., et al. (2008) · Movement Disorders · doi:10.1002/mds.22023 · Cited by 152
Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease
Beal, M. F. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70812-0 · Cited by 110
Self-citationMotor signs in the prodromal phase of Parkinson's disease
Maetzler, W., & Hausdorff, J. M. (2012) · Movement Disorders · doi:10.1002/mds.24973 · Cited by 104
Wang, X. L., Rainwater, D. L., Mahaney, M. C., & Stocker, R. (2004) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.3.649 · Cited by 98
Targeting mitochondrial dysfunction in neurodegenerative disease: Part II
Burchell, V., Gandhi, S., Deas, E., Wood, N. W., Abramov, A. Y., & Plun‐Favreau, H. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003730434 · Cited by 86
Therapeutic role of coenzyme Q10 in Parkinson's disease
Shults, C. W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.02.002 · Cited by 81
Self-citationConcurrent Administration of Coenzyme Q10 and α-Tocopherol Improves Learning in Aged Mice
Mcdonald, S. R., S. Sohal, R., & Forster, M. J. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.11.014 · Cited by 77
Mitochondrial therapies for Parkinson's disease
Thomas, B., & Beal, M. F. (2010) · Movement Disorders · doi:10.1002/mds.22781 · Cited by 62
Self-citationFranke, A. A., Morrison, C. M., Bakke, J., Custer, L. J., Li, X., & Cooney, R. V. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.03.002 · Cited by 49
A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts
Marras, C., Lang, A. E., Eberly, S. W., Oakes, D., Fahn, S., Schwid, S. R., Hyson, C., Shoulson, I., & of the Parkinson Study Group DATATOP and PRECEPT investigators (2009) · Movement Disorders · doi:10.1002/mds.22828 · Cited by 13
Self-citation
Cited by
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,825
Balestrino, R., & Schapira, A. H. V. (2020) · European Journal of Neurology · doi:10.1111/ene.14108 · Cited by 1,508
The role of oxidative stress in neurodegenerative diseases
Kim, G. H., Kim, J. E., Rhie, S. J., & Yoon, S. (2015) · Experimental Neurobiology · doi:10.5607/en.2015.24.4.325 · Cited by 1,355
Parkinson disease-associated cognitive impairment
Aarsland, D., Batzu, L., Halliday, G. M., Geurtsen, G. J., Ballard, C., Ray Chaudhuri, K., & Weintraub, D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00280-3 · Cited by 1,371
Fox, S. H., Katzenschlager, R., Lim, S., Barton, B., de Bie, R. M. A., Seppi, K., Coelho, M., Sampaio, C., & on behalf of the Movement Disorder Society Evidence‐Based Medicine Committee (2018) · Movement Disorders · doi:10.1002/mds.27372 · Cited by 1,002
Metadata
- Authors
- The Parkinson Study Group QE3 Investigators, Beal, M. F., Oakes, D., Shoulson, I., Henchcliffe, C., Galpern, W. R., Haas, R., Juncos, J. L., Nutt, J. G., Voss, T. S., Ravina, B., Shults, C. M., Helles, K., Snively, V., Lew, M. F., Griebner, B., Watts, A., Gao, S., Pourcher, E., Bond, L., Kompoliti, K., Agarwal, P., Sia, C., Jog, M., Cole, L., Sultana, M., Kurlan, R., Richard, I., Deeley, C., Waters, C. H., Figueroa, A., Arkun, A., Brodsky, M., Ondo, W. G., Hunter, C. B., Jimenez-Shahed, J., Palao, A., Miyasaki, J. M., So, J., Tetrud, J., Reys, L., Smith, K., Singer, C., Blenke, A., Russell, D. S., Cotto, C., Friedman, J. H., Lannon, M., Zhang, L., Drasby, E., Kumar, R., Subramanian, T., Ford, D. S., Grimes, D. A., Cote, D., Conway, J., Siderowf, A. D., Evatt, M. L., Sommerfeld, B., Lieberman, A. N., Okun, M. S., Rodriguez, R. L., Merritt, S., Swartz, C. L., Martin, W. R. W., King, P., Stover, N., Guthrie, S., Watts, R. L., Ahmed, A., Fernandez, H. H., Winters, A., Mari, Z., Dawson, T. M., Dunlop, B., Feigin, A. S., Shannon, B., Nirenberg, M. J., Ogg, M., Ellias, S. A., Thomas, C.-A., Frei, K., Bodis-Wollner, I., Glazman, S., Mayer, T., Hauser, R. A., Pahwa, R., Langhammer, A., Ranawaya, R., Derwent, L., Sethi, K. D., Farrow, B., Prakash, R., Litvan, I., Robinson, A., Sahay, A., Gartner, M., Hinson, V. K., Markind, S., Pelikan, M., Perlmutter, J. S., Hartlein, J., Molho, E., Evans, S., Adler, C. H., Duffy, A., Lind, M., Elmer, L., Davis, K., Spears, J., Wilson, S., Leehey, M. A., Hermanowicz, N., Niswonger, S., Shill, H. A., Obradov, S., Rajput, A., Cowper, M., Lessig, S., Song, D., Fontaine, D., Zadikoff, C., Williams, K., Blindauer, K. A., Bergholte, J., Propsom, C. S., Stacy, M. A., Field, J., Mihaila, D., Chilton, M., Uc, E. Y., Sieren, J., Simon, D. K., Kraics, L., Silver, A., Boyd, J. T., Hamill, R. W., Ingvoldstad, C., Young, J., Thomas, K., Kostyk, S. K., Wojcieszek, J., Pfeiffer, R. F., Panisset, M., Beland, M., Reich, S. G., Cines, M., Zappala, N., Rivest, J., Zweig, R., Lumina, L. P., Hilliard, C. L., Grill, S., Kellermann, M., Tuite, P., Rolandelli, S., Kang, U. J., Young, J., Rao, J., Cook, M. M., Severt, L., & Boyar, K.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2014-05-01
- Volume
- 71
- Issue
- 5
- Pages
- 543
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2069650508
- Cited by
- 408
- References
- 27
- FWCI
- 12.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.